LENZ Therapeutics, Inc. LENZ 深 滬
已收盤 05-08 16:00:00 美东时间
10.06
+0.340
+3.50%
華盛通- 最 高10.10
- 今 開9.81
- 成交量 64.02万股
- 最 低 9.60
- 昨 收 9.72
- 總市值 3.15亿
- 52周最高 50.40
- 市盈率 靜 --
- 換手率 2.04%
- 52周最低 8.25
- 委 比 -59.77%
- 總股本 3135.44万
- 歷史最高 230.79
- 量 比 0.72
- 振 幅 5.14%
- 歷史最低 3.92
- 每 手 1
- 風險率 11.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
LENZ Therapeutics Files Marketing Authorization Application Review, Approval Of VIZZ To Medicines And Healthcare products Regulatory Agency To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the review
04-20 20:04
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $52 to $26.
03-26 23:42
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share
03-24 20:01
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings
LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.
03-24 04:32
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.
01-31 02:02
